{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T06:00:32Z","timestamp":1775196032148,"version":"3.50.1"},"reference-count":35,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,4,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Vaccination using irradiated, adenovirus transduced autologous myeloblasts to secrete granulocyte\u2013macrophage colony-stimulating factor (GVAX) early after allogeneic hematopoietic stem cell transplantation (HSCT) can induce potent immune responses. We conducted a randomized phase 2 trial of GVAX after HSCT for myelodysplastic syndrome with excess blasts or relapsed\/refractory acute myeloid leukemia. Myeloblasts were harvested before HSCT to generate the vaccine. Randomization to GVAX vs placebo (1:1) was stratified according to disease, transplant center, and conditioning. Graft-versus-host disease (GVHD) prophylaxis included tacrolimus and methotrexate. GVAX or placebo vaccination was started between day 30 and 45 if there was engraftment and no GVHD. Vaccines were administered subcutaneously\/intradermally weekly \u00d7 3, then every 2 weeks \u00d7 3. Tacrolimus taper began after vaccine completion. A\u00a0total of 123 patients were enrolled, 92 proceeded to HSCT, and 57 (GVAX, n = 30; placebo, n = 27) received at least 1 vaccination. No Common Toxicity Criteria grade 3 or worse vaccine-related adverse events were reported, but injection site reactions were more common after GVAX (10 vs 1; P = .006). With a median follow-up of 39 months (range, 9-89 months), 18-month progression-free survival, overall survival, and relapse incidence were 53% vs 55% (P = .79), 63% vs 59% (P = .86), and 30% vs 37% (P = .51) for GVAX and placebo, respectively. Nonrelapse mortality at 18 months was 17% vs 7.7% (P\u00a0= .18), grade II to IV acute GVHD at 12 months was 34% vs 12% (P = .13), and chronic GVHD at 3 years was 49% vs 57% for GVAX and placebo (P = .26). Reconstitution of T, B, and natural killer cells was not decreased or enhanced by GVAX. There were no differences in serum major histocompatibility chain-related protein A\/B or other immune biomarkers between GVAX and placebo. GVAX does not improve survival after HSCT for myelodysplastic syndrome\/acute myeloid leukemia. This trial was registered at www.clinicaltrials.gov as #NCT01773395.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021006255","type":"journal-article","created":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T21:01:41Z","timestamp":1637614901000},"page":"2183-2194","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":20,"title":["GM-CSF secreting leukemia cell vaccination for MDS\/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial"],"prefix":"10.1182","volume":"6","author":[{"given":"Vincent T.","family":"Ho","sequence":"first","affiliation":[{"name":"Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haesook T.","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Data Science, Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Brock","sequence":"additional","affiliation":[{"name":"Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilene","family":"Galinsky","sequence":"additional","affiliation":[{"name":"Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Daley","sequence":"additional","affiliation":[{"name":"Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Augustine","family":"Weber","sequence":"additional","affiliation":[{"name":"Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8376-0344","authenticated-orcid":false,"given":"Olga","family":"Pozdnyakova","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariano","family":"Severgnini","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Nikiforow","sequence":"additional","affiliation":[{"name":"Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corey","family":"Cutler","sequence":"additional","affiliation":[{"name":"Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Koreth","sequence":"additional","affiliation":[{"name":"Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"Edwin P.","family":"Alyea","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Duke Cancer Institute, Durham, NC;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph H.","family":"Antin","sequence":"additional","affiliation":[{"name":"Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahasweta","family":"Gooptu","sequence":"additional","affiliation":[{"name":"Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rizwan","family":"Romee","sequence":"additional","affiliation":[{"name":"Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman","family":"Shapiro","sequence":"additional","affiliation":[{"name":"Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Bin","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Massachusetts General Hospital, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacalyn","family":"Rosenblatt","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Avigan","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. Stephen","family":"Hodi","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenn","family":"Dranoff","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3348-5054","authenticated-orcid":false,"given":"Catherine J.","family":"Wu","sequence":"additional","affiliation":[{"name":"Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerome","family":"Ritz","sequence":"additional","affiliation":[{"name":"Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Soiffer","sequence":"additional","affiliation":[{"name":"Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2022,3,31]]},"reference":[{"issue":"22","key":"2022033115291455400_B1","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","article-title":"Reduced mortality after allogeneic hematopoietic-cell transplantation","volume":"363","author":"Gooley","year":"2010","journal-title":"N Engl J Med."},{"issue":"7","key":"2022033115291455400_B2","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1073\/pnas.0307298101","article-title":"IL-15 enhances the in\u00a0vivo antitumor activity of tumor-reactive CD8+ T cells","volume":"101","author":"Klebanoff","year":"2004","journal-title":"Proc Natl Acad Sci USA."},{"issue":"2","key":"2022033115291455400_B3","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood-2003-09-3344","article-title":"Interleukin-15 enhances immune reconstitution after allogeneic bone marrow transplantation","volume":"105","author":"Alpdogan","year":"2005","journal-title":"Blood."},{"issue":"12","key":"2022033115291455400_B4","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.bbmt.2005.08.032","article-title":"Interleukin 12 is associated with reduced relapse without increased incidence of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation","volume":"11","author":"Reddy","year":"2005","journal-title":"Biol Blood Marrow Transplant."},{"issue":"7","key":"2022033115291455400_B5","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1084\/jem.20071681","article-title":"Administration of rhIL-7 in humans increases in\u00a0vivo TCR repertoire diversity by preferential expansion of naive T cell subsets","volume":"205","author":"Sport\u00e8s","year":"2008","journal-title":"J Exp Med."},{"issue":"8","key":"2022033115291455400_B6","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1073\/pnas.90.8.3539","article-title":"Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity","volume":"90","author":"Dranoff","year":"1993","journal-title":"Proc Natl Acad Sci USA."},{"issue":"17","key":"2022033115291455400_B7","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1200\/JCO.2003.07.005","article-title":"Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma","volume":"21","author":"Soiffer","year":"2003","journal-title":"J Clin Oncol."},{"issue":"22","key":"2022033115291455400_B8","doi-asserted-by":"crossref","first-page":"13141","DOI":"10.1073\/pnas.95.22.13141","article-title":"Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma","volume":"95","author":"Soiffer","year":"1998","journal-title":"Proc Natl Acad Sci USA."},{"issue":"11","key":"2022033115291455400_B9","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1182\/blood.V104.11.441.441","article-title":"Posttransplant immunotherapy with a GM-CSF-based tumor vaccine (GVAX) following autologous stem cell transplant (ASCT) for acute myeloid leukemia (AML)","volume":"104","author":"DeAngelo","year":"2004","journal-title":"Blood."},{"issue":"11","key":"2022033115291455400_B10","article-title":"A phase I study of vaccination with lethally irradiated, autologous myeloblasts engineered by adenoviral mediated gene transfer to secrete human granulocyte-macrophage colony stimulating factor","volume":"98","author":"DeAngelo","year":"2001"},{"issue":"24","key":"2022033115291455400_B11","doi-asserted-by":"crossref","first-page":"9190","DOI":"10.1073\/pnas.0603503103","article-title":"Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity","volume":"103","author":"Jinushi","year":"2006","journal-title":"Proc Natl Acad Sci USA."},{"issue":"10","key":"2022033115291455400_B12","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.4049\/jimmunol.156.10.3858","article-title":"Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity","volume":"156","author":"Levitsky","year":"1996","journal-title":"J Immunol."},{"issue":"6","key":"2022033115291455400_B13","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1073\/pnas.0530311100","article-title":"Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction","volume":"100","author":"Schmollinger","year":"2003","journal-title":"Proc Natl Acad Sci USA."},{"issue":"24","key":"2022033115291455400_B14","doi-asserted-by":"crossref","first-page":"10150","DOI":"10.1158\/0008-5472.CAN-10-1852","article-title":"Active immunotherapy induces antibody responses that target tumor angiogenesis","volume":"70","author":"Schoenfeld","year":"2010","journal-title":"Cancer Res."},{"issue":"1","key":"2022033115291455400_B15","first-page":"162","article-title":"Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation","volume":"61","author":"Teshima","year":"2001","journal-title":"Cancer Res."},{"issue":"37","key":"2022033115291455400_B16","doi-asserted-by":"crossref","first-page":"15825","DOI":"10.1073\/pnas.0908358106","article-title":"Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation","volume":"106","author":"Ho","year":"2009","journal-title":"Proc Natl Acad Sci USA."},{"issue":"5","key":"2022033115291455400_B17","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1158\/1078-0432.CCR-14-1956","article-title":"Angiogenic cytokines are antibody targets during graft-versus-leukemia reactions","volume":"21","author":"Piesche","year":"2015","journal-title":"Clin Cancer Res."},{"issue":"4","key":"2022033115291455400_B18","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1200\/JCO.2003.03.091","article-title":"Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma","volume":"21","author":"Salgia","year":"2003","journal-title":"J Clin Oncol."},{"issue":"6","key":"2022033115291455400_B19","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant."},{"issue":"5","key":"2022033115291455400_B20","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1182\/blood-2015-10-672345","article-title":"Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD","volume":"127","author":"Alho","year":"2016","journal-title":"Blood."},{"issue":"2","key":"2022033115291455400_B21","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1182\/bloodadvances.2020003005","article-title":"Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide","volume":"5","author":"Rambaldi","year":"2021","journal-title":"Blood Adv."},{"issue":"10","key":"2022033115291455400_B22","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1007\/s00262-021-02910-x","article-title":"Immune modulating activity of the CHK1 inhibitor prexasertib and anti-PD-L1 antibody LY3300054 in patients with high-grade serous ovarian cancer and other solid tumors","volume":"70","author":"Do","year":"2021","journal-title":"Cancer Immunol Immunother."},{"issue":"8","key":"2022033115291455400_B23","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1007\/s00262-021-02855-1","article-title":"Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors","volume":"70","author":"Tyan","year":"2021","journal-title":"Cancer Immunol Immunother."},{"issue":"2","key":"2022033115291455400_B24","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/1740774512436614","article-title":"Three-component cure rate model for nonproportional hazards alternative in the design of randomized clinical trials","volume":"9","author":"Kim","year":"2012","journal-title":"Clin Trials."},{"key":"2022033115291455400_B25","volume-title":"Classification and Regression Trees: Wadsworth Statistics\/Probability.","author":"Breiman","year":"1984","edition":"1st ed"},{"key":"2022033115291455400_B26","author":"Therneau","year":"1997"},{"issue":"20","key":"2022033115291455400_B27","first-page":"5160","article-title":"Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer","volume":"59","author":"Simons","year":"1999","journal-title":"Cancer Res."},{"issue":"4","key":"2022033115291455400_B28","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/jnci\/djh028","article-title":"Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer","volume":"96","author":"Nemunaitis","year":"2004","journal-title":"J Natl Cancer Inst."},{"issue":"14","key":"2022033115291455400_B29","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1158\/1078-0432.CCR-14-2932","article-title":"Biologic activity of autologous, granulocyte-macrophage colony-stimulating factor secreting alveolar soft-part sarcoma and clear cell sarcoma vaccines","volume":"21","author":"Goldberg","year":"2015","journal-title":"Clin Cancer Res."},{"issue":"5","key":"2022033115291455400_B30","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1158\/1078-0432.CCR-20-2974","article-title":"Vaccine-induced intratumoral lymphoid aggregates correlate with survival following treatment with a neoadjuvant and adjuvant vaccine in patients with resectable pancreatic adenocarcinoma","volume":"27","author":"Zheng","year":"2021","journal-title":"Clin Cancer Res."},{"issue":"18","key":"2022033115291455400_B31","doi-asserted-by":"crossref","first-page":"5493","DOI":"10.1158\/1078-0432.CCR-18-2992","article-title":"Results from a Phase IIb, randomized, multicenter study of GVAX pancreas and CRS-207 compared with chemotherapy in adults with previously treated metastatic pancreatic adenocarcinoma (ECLIPSE study)","volume":"25","author":"Le","year":"2019","journal-title":"Clin Cancer Res."},{"issue":"19","key":"2022033115291455400_B32","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.1158\/1078-0432.CCR-20-1025","article-title":"A phase II study of allogeneic GM-CSF-transfected pancreatic tumor vaccine (GVAX) with ipilimumab as maintenance treatment for metastatic pancreatic cancer","volume":"26","author":"Wu","year":"2020","journal-title":"Clin Cancer Res."},{"issue":"13","key":"2022033115291455400_B33","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1158\/1078-0432.CCR-19-3372","article-title":"T-cell infiltration and adaptive Treg resistance in response to androgen deprivation with or without vaccination in localized prostate cancer","volume":"26","author":"Obradovic","year":"2020","journal-title":"Clin Cancer Res."},{"issue":"17","key":"2022033115291455400_B34","doi-asserted-by":"crossref","first-page":"6337","DOI":"10.1158\/0008-5472.CAN-04-0757","article-title":"High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells","volume":"64","author":"Serafini","year":"2004","journal-title":"Cancer Res."},{"issue":"18","key":"2022033115291455400_B35","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1200\/JCO.2006.08.5829","article-title":"Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine","volume":"25","author":"Filipazzi","year":"2007","journal-title":"J Clin Oncol."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/7\/2183\/1884748\/advancesadv2021006255.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/7\/2183\/1884748\/advancesadv2021006255.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T00:43:48Z","timestamp":1673829828000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/7\/2183\/482726\/GM-CSF-secreting-leukemia-cell-vaccination-for-MDS"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,31]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,4,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021006255","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,31]]}}}